Современная антигипертензивная терапия: возможности уникальной российской фиксированной комбинации рамиприла и индапамида

Совет Экспертов Российского кардиологического общества (РКО)

Артериальная гипертензия, фиксированная комбинация, рамиприл, индапамид

1. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119(2):243-50. doi:10.1161/CIRCULATIONAHA.108.797936.

2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [published correction appears in J Hypertens. 2019;37(1):226]. J Hypertens. 2018;36(10):1953-2041. doi:10.1097/HJH.0000000000001940.

3. Муромцева Г. А., Концевая А. В., Константинов В. В., и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11. doi:10.15829/1728-8800-2014-6-4-11.

4. Бойцов С. А., Баланова Ю. А., Шальнова С. А., и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;4:4-14. doi:10.15829/1728-8800-2014-4-4-14.

5. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23. doi:10.1016/S0140-6736(05)17741-1.

6. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.

7. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957-67. doi:10.1016/S0140-6736(15)01225-8.

8. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens. 2015;33:1321-41. doi:10.1097/HJH.0000000000000614.

9. Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens. 2005;23:2113-18. doi:10.1097/01.hjh.0000194114.12228.16.

10. Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26:1282-89. doi:10.1097/HJH.0b013e328306ebe2.

11. Smith W, Ball SG. Ramipril. Int J Clin Pract 2000;54:255-60.

12. Unger T, Ganten D, Lang RE. Tissue converting enzyme and cardiovascular actions of converting enzyme inhibitors. J Cardiovasc Pharmacol. 1986;8(suppl 10):S75-81. doi:10.1097/00005344-198600101-00015.

13. Zhuo JL, Mendelsohn FA, Ohishi M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension. 2002;39(2 pt 2):634-38. doi:10.1161/hy0202.103417.

14. Ferrari R. Preserving bradykinin or blocking angiotensin II: the cardiovascular dilemma. Dialogues Cardiovasc Med. 2004;9(2):71-89.

15. Morgan T, Anderson A. Clinical efficacy of perindopril in hypertension. Clin Exp Pharmacol Physiol Suppl. 1992;19:61-5. doi:10.1111/j.1440-1681.1992.tb02812.x.

16. Famsworth A. Angiotensin-converting enzyme inhibitors in heart failure: target dose prescription in elderly patients. Age Ageing. 1998:27(5):653-54. doi:10.1093/ageing/27.5.653.

17. Ceconi C, Francolini G, Olivares A, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007;577(1-3):1-6. doi:10.1016/j.ejphar.2007.07.061.

18. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet. 1998;34:457-82. doi:10.2165/00003088-199834060-00003.

19. Rosenthal J, Buehler G, Koenig W, Rangoonwala B. Effect of angiotensin converting enzyme inhibition on human tissue renin. J Cardiovasc Pharmacol. 1991;18(suppl 2):S122-4.

20. Miyazaki M, Kawamoto T, Okunishi H. Vascular affinity of trandolapril. Am J Hypertens. 1995;8(10 pt 2):63S-7S. doi:10.1016/0895-7061(95)00191-3.

21. Plosker GL, Sorkin EM. Quinapril: a reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders. Drugs. 1994;48:227-52. doi:10.2165/00003495-199448020-00008.

22. Package insert. Altace (ramipril). Kansas City, MO: Aventis Pharmaceuticals, July 2001.

23. Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet. 1994;26:7-15. doi:10.2165/00003088-199426010-00002.

24. Frampton JE, Peters DH. Ramipril: an updated review of its therapeutic use in essential hypertension and heart failure. Drugs. 1995;49:440-66. doi:10.2165/00003495199549030-00008.

25. van Griensven JM, Schoemaker RC, Cohen AF, et al. Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. Eur J Clin Pharmacol. 1995;47:513-18. doi:10.1007/bf00193704.

26. Altace Pharmacology. Available at: www.rxlist.com/cgi/generic/ramipril_cp.htm.

27. Witte PU, Walter U. Comparative double-blind study of ramipril and captopril in mild to moderate hypertension. Am J Cardiol. 1987;59:115D-20D. doi:10.1016/0002-9149(87)90065-8.

28. Ruddy MC, Mroczek WJ. Comparison of ramipril and enalapril in patients with essential hypertension. Pharmacotherapy. 1993;13:224-28.

29. Lenox-Smith AJ, Street RB, Kendall FD. Comparison of ramipril against atenolol in controlling mild to moderate hypertension. J Cardiovasc Pharmacol. 1991;18(suppl 2):S150-52.

30. Heidbreder D, Froer KL, Breitstadt A, et al. Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: part 1 — a double-blind, comparative, multicenter study in nonresponders to ramipril monotherapy. Clin Cardiol. 1992;15:90410. doi:10.1002/clc.4960151210.

31. Scholze J, Breitstadt A, Cairns V, et al. Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group. J Hypertens. 1993;11:217-21. doi:10.1097/00004872-199302000-00015.

32. Bainbridge AD, Macfadyen RJ, Stark S, et al. The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension. Br J Clin Pharmacol. 1993;36:323-30. doi:10.1111/j.1365-2125.1993.tb00371.x.

33. Poisson P, Bauer B, Schueler E, Rangoonwala B. Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy. Curr Med Res Opin. 1996;13:445-56. doi:10.1185/03007999609115225.

34. Lonn E, Shaikholeslami R, Yi Q, et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol. 2004;43:2200-06. doi:10.1016/j.jacc.2003.10.073.

35. Foster RE, Johnson DB, Barilla F, et al. Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction. Am Heart J. 1998;136:269-75. doi:10.1053/hj.1998.v136.89405.

36. Nielsen FS, Sato A, Ali S, et al. Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients. Diabetes Care. 1998;21:804-09. doi:10.2337/diacare.21.5.804.

37. Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute MI: the healing and early afterload reducing therapy trial. Circulation. 1997;95:2643-51. doi:10.1161/01.cir.95.12.2643.

38. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-28.

39. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE extension (AIREX) study. Lancet. 1997;349:1493-97. doi:10.1016/s0140-6736(97)04442-5.

40. Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting enzyme inhibition post revascularization study (APRES). J Am Coll Cardiol. 2000;35:881-88. doi:10.1016/s0735-1097(99)00634-8.

41. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. doi:10.1056/NEJM200001203420301.

42. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782-88. doi:10.1016/s0140-6736(03)14286-9.

43. Tu K, Mamdani MM, Jacka RM, et al. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ. 2003;168(5):553-55.

44. Malik IS, Bhatia VK, Kooner JS. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart. 2001;85:539-43. doi:10.1136/heart.85.5.539.

45. Carroll CA. Economic impact of ramipril on hospitalization of high-risk cardiovascular patients. Ann Pharmacother. 2003;37:327-31. doi:10.1345/aph.1C125.

46. Erhardt L, Ball S, Andersson F, et al. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy. Pharmacoeconomics. 1997;12:256-66. doi:10.2165/00019053-199712020-00016.

47. Hollander W, Wilkins RW. Chlorothiazide: a new type of drug for the treatment of hypertension. BMQ 1957;8:68-75.

48. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs–overview and meta-analyses. J Hypertens. 2015;33:195-211. doi:10.1097/HJH.0000000000000447.

49. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26:819-24. doi:10.1097/HJH.0b013e3282f4edd7.

50. Brown MJ, Williams B, Morant SV, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4:136-47. doi:10.1016/S2213-8587(15)00377-0.

51. Leonetti G, Rappelli A, Salvetti A, et al. Long-term effects of indapamide: final results of a 2-year Italian multicenter study in systemic hypertension. Am J Cardiol. 1990;65:67-71. doi:10.1016/0002-9149(90)90347-4.

52. Chaffman M, Heel RC, Brodgen RN, et al. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1984;28(3):189-235. doi:10.2165/00003495-198428030-00001.

53. Senior R, Imbs JL, Bory M, et al. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. J Cardiovasc Pharmacol. 1993;22 Suppl 6:S106-S10.

54. Carey PA, Sheridan DJ, de Cordoue A, Guez D. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol. 1996;77(6):17b-9b. doi:10.1016/s0002-9149(97)89234-x.

55. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol. 1996;77(6):12b-6b. doi:10.1016/s0002-9149(97)89233-8.

56. Leonetti G, Rappelli A, Salvetti A, Scapellato L. Tolerability and well-being with indapamide in the treatment of mild-moderate hypertension. An Italian multicenter study. Am J Med. 1988;84(1B):59-64.

57. Bataillard A, Schiavi P, Sassard J. Pharmacological properties of indapamide. Rationale for use in hypertension. Clin Pharmacokinet. 1999;37 Suppl 1:7-12. doi:10.2165/00003088199937001-00002.

58. Emeriau JP, Knauf H, Pujadas JO, et al. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens. 2001;19(2):343-50. doi:10.1097/00004872-200102000-00023.

59. Baguet JP, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs. 2005;5(2):131-40. doi:10.2165/00129784-200505020-00007.

60. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000;18(10):1465-75. doi:10.1097/00004872-200018100-00015.

61. Puig JG, Marre M, Kokot F, et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens. 2007;20(1):90-7. doi:10.1016/j.amjhyper.2006.05.018.

62. London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. Am J Hypertens. 2006;19(1):113-21. doi:10.1016/j.amjhyper.2005.06.027.

63. Asmar RG, London GM, O’Rourke ME, Safar ME; REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38(4):922-26. doi:10.1161/hy1001.095774.

64. PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressurelowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358(9287):1033-41. doi:10.1016/S0140-6736(01)06178-5.

65. Bloch MJ, Basile JN. Treating hypertension in the oldest of the old reduces total mortality: results of the Hypertension in the Very Elderly Trial (HYVET). J Clin Hypertens (Greenwich). 2008;10(6):501-3. doi:10.1111/j.1751-7176.2008.08056.x.

66. Fuenmayor NT, Moreira E, de los Rios V, et al. Relations between fasting serum insulin, glucose, and dihydroepiandrosterone-sulfate concentrations in obese patients with hypertension: short-term effects of antihypertensive drugs. J Cardiovasc Pharmacol. 1997;30(4):523-27. doi:10.1097/00005344-199710000-00018.

67. Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens. 1995;8(5 Pt 1):461-66. doi:10.1016/0895-7061(95)00055-T.

68. Matsuzaki M, Ogihara T, Umemoto S, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29(8):1649-59. doi:10.1097/HJH.0b013e328348345d.

69. MacDonald TM, Williams B, Webb DJ, et al. Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial. J Am Heart Assoc. 2017;6(11):e006986. Published 2017 Nov 18. doi:10.1161/JAHA.117.006986.

70. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124-31. doi:10.1161/HYPERTENSIONAHA.112.194167.

71. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28(7):1584-90. doi:10.1097/HJH.0b013e328339f9fa.

72. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig. 2012;32(10):649-64. doi:10.1007/bf03261919.